Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

Wang, Jack; Wu, Chen‐Yi; Yeh, Yi-Cheng; Shyr, Yi‐Ming; Wu, Ying-Ying; Kuo, Chen‐Yu; Hung, Yi‐Ping; Chen, Ming-Huang; Lee, Wei-Ping; Luo, Jiing‐Chyuan; Chao, Yee; Li, Chung–Pin

doi:10.18632/oncotarget.4216

Cited by 96 publications

(74 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…57 A more-recent randomized trial conducted in Taiwan reported a median overall survival of 7.2 months in patients treated with erlotinib plus gemcitabine versus 4.4 months among those treated with gemcitabine alone. 58 …”

Section: Mapk Pathway Inhibitorsmentioning

confidence: 99%

The influence of subclonal resistance mutations on targeted cancer therapy

2015

View full text Add to dashboard Cite

Clinical oncology is being revolutionized by the increasing use of molecularly targeted therapies. This paradigm holds great promise for improving cancer treatment; however, allocating specific therapies to the patients who are most likely to derive a durable benefit continues to represent a considerable challenge. It is becoming increasingly clear that cancers are characterized by extensive intratumour genetic heterogeneity, and that patients being considered for treatment with a targeted agent might, therefore, already possess resistance to the drug in a minority of cells. Indeed, multiple examples of pre-existing subclonal resistance mutations to various molecularly targeted agents have been described, which we review herein. Early detection of pre-existing or emerging drug resistance could enable more personalized use of targeted cancer therapy, as patients could be stratified to receive the therapies that are most likely to be effective. We consider how monitoring of drug resistance could be incorporated into clinical practice to optimize the use of targeted therapies in individual patients.

show abstract

Section: Mapk Pathway Inhibitorsmentioning

confidence: 99%

The influence of subclonal resistance mutations on targeted cancer therapy

2015

View full text Add to dashboard Cite

show abstract

“…Considering this, EGFR targeted therapies can be rescued in PDAC patients whose tumours bearing wild type KRAS and overexpressing EGFR. Evidently, in a randomized, open-label, prospective trial, adjuvant cemotherapy gemcitabine plus erlotinib was found to be more effective than gemcitabine alone for treating metastatic PDAC, especially those with EGFR mutations (ClinicalTrials.gov number, NCT01608841) [264].…”

Section: Use Of Biomarkers To Guide Therapymentioning

confidence: 99%

Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

Korhan¹,

Verkerk²,

Critchley³

2017

Integr Mol Med

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) arises from epithelia of pancreas. Despite its low incidence, it is the most lethal cancer type. Although the poor outcome is largely secondary to the high proportion of patients who are diagnosed with advanced disease, the prognosis of PDAC is also influenced by the inherent biological aggressiveness and the high metastatic potential of this malignancy. Treatment options remain limited with little progress over the last decades. Some improvements in surgical outcome occur in patients who also receive chemotherapy and/or radiotherapy, however, the impact on long-term survival has been minimal owing to the intense resistance of PDAC to all extent treatments regimen. Hence, there is an urgent need to 1) gain better understanding of the biology of PDAC; 2) to develop early detection and prevention programs; 3) to identify new therapeutic strategies to improve quality of life and survivorship. In this review, first, we will summarise the state of knowledge of PDAC pathogenesis with a particular the focus on the molecular characteristics causing therapeutic resistance. Then, we will briefly review current and emerging approaches in the PDAC care. Lastly, we will highlight the integrative approaches in the light of new experimental and clinical research conducted with the aim of moving towards personalised therapy in patients with PDAC.

show abstract

“…In recent years, targeted therapies have been tested for treating metastatic pancreatic cancer, for example Erlotinib, an inhibitor of the epidermal growth factor receptor (EGFR) (ClinicalTrials.gov number NCT01608841), is a successful example of how using an antibody, in combination with gemcitabine-based chemotherapy, is effective in improving overall and progression-free survival, as well as response rates in metastatic PDA patients [6].…”

Section: Alpha-enolase (Eno1) and Anti-eno1 Antibody-based Immunotherapymentioning

confidence: 99%

Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer

Principe¹,

Cappello²,

Novelli³

2016

Chemotherapy

View full text Add to dashboard Cite

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial

Cited by 96 publications

References 40 publications

The influence of subclonal resistance mutations on targeted cancer therapy

The influence of subclonal resistance mutations on targeted cancer therapy

Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

Blockade of Surface Alpha-Enolase (ENO1) as a Novel Immunotherapeutic Approach in Pancreatic Cancer

Contact Info

Product

Resources

About